Zobrazeno 1 - 10
of 367
pro vyhledávání: '"Satoru, Iwasa"'
Autor:
Toru Kadono, Satoru Iwasa, Toshiharu Hirose, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Atsuo Takashima, Ken Kato
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Background Nivolumab was approved for the treatment of advanced gastric cancer in 2017 in Japan. The aim of this study was to assess the impact of nivolumab in a real‐world clinical setting. Methods This single‐institutional retrospectiv
Externí odkaz:
https://doaj.org/article/fe41231595f14b45a5600e716b2861f8
Autor:
Toru Kadono, Satoru Iwasa, Kengo Nagashima, Kotoe Oshima, Shun Yamamoto, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Yoshitaka Honma, Atsuo Takashima, Ken Kato, Toshikazu Ushijima, Narikazu Boku
Publikováno v:
Cancer Medicine, Vol 12, Iss 8, Pp 9322-9331 (2023)
Abstract Background While the efficacy of immune checkpoint inhibitors (ICIs) reportedly varies among metastatic sites and progression patterns (classified as systemic progression [SP] or mixed progression [MP]), the clinical efficacy of ICIs against
Externí odkaz:
https://doaj.org/article/ede32e6300aa451ea9bc656aaed18946
Autor:
Satoru Iwasa, Zi‐Xian Wang, Kei Muro, Satoshi Morita, Young Suk Park, Dongsheng Zhang, Yasuhide Yamada, Junichi Sakamoto, Tae Won Kim
Publikováno v:
Cancer Communications, Vol 43, Iss 4, Pp 519-522 (2023)
Externí odkaz:
https://doaj.org/article/8a4d3abd047443ceb9637dd494c11d93
Autor:
Hibiki Udagawa, Shunji Takahashi, Motohiro Hirao, Makoto Tahara, Satoru Iwasa, Yasuyoshi Sato, Takuya Hamakawa, Kohei Shitara, Hidehito Horinouchi, Keisho Chin, Norikazu Masuda, Takuya Suzuki, Shiori Okumura, Takao Takase, Reiko Nagai, Kan Yonemori
Publikováno v:
Cancer Medicine, Vol 12, Iss 2, Pp 1269-1278 (2023)
Abstract Background In this open‐label, Phase 1 study, we explore the safety and efficacy of E7389‐LF (liposomal formulation of eribulin) in Japanese patients with advanced solid tumors. Methods This open‐label, Phase 1 study enrolled Japanese
Externí odkaz:
https://doaj.org/article/73b26d485732490b8b8d2a682fc73707
Autor:
Shigemasa Takamizawa, Hirokazu Shoji, Hidekazu Hirano, Koji Izutsu, Shun Yamamoto, Satoru Iwasa, Yoshitaka Honma, Natsuko Okita, Atsuo Takashima, Ken Kato, Narikazu Boku
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 1, Pp 85-89 (2021)
Severe thrombocytopenia is a rare adverse event of panitumumab. Here, we report the first patient with metastatic colorectal cancer who developed severe thrombocytopenia, diagnosed as panitumumab-associated drug-induced immune thrombocytopenia (DITP)
Externí odkaz:
https://doaj.org/article/f7f9deb3fbdd495a9e8697a053be6d2d
Autor:
Yoshitaka Honma, Kengo Nagashima, Hidekazu Hirano, Hirokazu Shoji, Satoru Iwasa, Atsuo Takashima, Natsuko Okita, Ken Kato, Narikazu Boku, Naoya Murakami, Kouji Inaba, Yoshinori Ito, Jun Itami, Jun Kanamori, Junya Oguma, Hiroyuki Daiko
Publikováno v:
Cancer Medicine, Vol 9, Iss 2, Pp 595-604 (2020)
Abstract Background Neuroendocrine carcinoma (NEC) arising from the esophagus (EsoNEC) is extreme rare, accounting for approximately 1% of esophageal cancer. Even for localized NEC, multidisciplinary approach including chemotherapy is recommended in
Externí odkaz:
https://doaj.org/article/ede5c4ed87014da483130fa21447523e
Autor:
Kotoe Oshima, Hidekazu Hirano, Hirokazu Shoji, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Narikazu Boku
Publikováno v:
PLoS ONE, Vol 17, Iss 6 (2022)
Background Trifluridine/tipiracil (TFTD), with or without bevacizumab (Bev), and regorafenib are salvage chemotherapy options for metastatic colorectal cancer (mCRC). Here, we examined the influence of precedent drug on the efficacy of subsequent dru
Externí odkaz:
https://doaj.org/article/23096a332ce14b679e99eae3943fe4c7
Autor:
MAYU YADA, SHUN YAMAMOTO, YOSHITAKA HONMA, HIDEKAZU HIRANO, NATSUKO OKITA, HIROKAZU SHOJI, SATORU IWASA, ATSUO TAKASHIMA, AKIHITO NAGAHARA, KEN KATO
Publikováno v:
In Vivo; Mar/Apr2024, Vol. 38 Issue 2, p761-766, 6p
Autor:
Ken Masuda, Hirokazu Shoji, Kengo Nagashima, Shun Yamamoto, Masashi Ishikawa, Hiroshi Imazeki, Masahiko Aoki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Narikazu Boku
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Abstract Background Recent studies have shown that immune-related adverse events (irAEs) caused by immune checkpoint inhibitors were associated with clinical benefit in patients with melanoma or lung cancer. In advanced gastric cancer (AGC) patients,
Externí odkaz:
https://doaj.org/article/7a4e76f42936477f8c32d0e12dbecb95
Autor:
Kohei Shitara, Taroh Satoh, Satoru Iwasa, Kensei Yamaguchi, Kei Muro, Yoshito Komatsu, Tomohiro Nishina, Taito Esaki, Jun Hasegawa, Yasuyuki Kakurai, Emi Kamiyama, Tomoko Nakata, Kota Nakamura, Hayato Sakaki, Ichinosuke Hyodo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Abstract Background Erythropoietin-producing hepatocellular receptor A2 (EPHA2) is overexpressed on the cell surface in many cancers and predicts poor prognosis. DS-8895a is a humanized anti-EPHA2 IgG1 monoclonal antibody afucosylated to enhance anti
Externí odkaz:
https://doaj.org/article/e6e7417efabc4c09a8c6af99cb58e3cb